>>Description of the research protocol "KHB-1801 / 1009535"

A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration
Phase III study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : DMLA Humide
Brugmann identifier : KHB-1801 / 1009535
EudraCT identifier : 2017-004825-34


Involved department : Ophthalmology
Principal investigator : Postelmans
Sponsor : Cheng Du
Contact : Clinical Research Unit

>This protocol was approved by the Brugmann (CE Central) ethics committee.